1. Merck published a report detailing the average list price increases and net prices, which exclude rebates and other discounts traditionally paid by drugmakers, for its therapies. Januvia is one of Merck’s best-selling drugs. (Business Insider)
2. It’s unclear whether President Trump’s memo freezing federal hires will affect the FDA. Trump had said the government could continue to fill positions that address “public safety responsibilities” but did not clarify what that means. (Stat)
3. Sanofi said it will pay $61.5 million to settle a class dispute alleging that the drugmaker violated antitrust laws by using its market power to require bundling-pricing contracts for some of its vaccines. (Law360)
4. Ogilvy consolidated its brands into “a single, branded, integrated operating company.” This includes the U.S. market, in which Ogilvy now operates as one P&L. (Campaign)
5. ICYMI: Endo International cut 90 positions as part of a restructuring. The layoffs included the elimination of its U.S. branded pain field sales force. (Drug Delivery Business News)
